<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01052792</url>
  </required_header>
  <id_info>
    <org_study_id>CR-BE-138-NAPR-2005</org_study_id>
    <nct_id>NCT01052792</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Naproxen Sodium 550 mg Tablets Under Fed Conditions</brief_title>
  <official_title>Open Label Randomised,Two-treatment,Two-period,Two-sequence,Single-dose, Crossover,Comparative Bioequivalence Study of Naproxen Sodium 550 mg Tablets With ANAPROX® DS 550 mg Tablets in Healthy,Adult, Human Subjects Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label randomised, two-treatment,two-period, two-sequence, single-dose, crossover,
      comparative bioequivalence study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was an open label, randomised, two-treatment,two-period, two-sequence, single-dose,
      crossover,comparative bioequivalence study of Naproxen Sodium 550 mg tablets (containing
      naproxen 500 mg) manufactured by Dr. Reddy's Laboratories, ltd, Generics, India compared with
      ANAPROX® DS 550 mg tablets (containing naproxen 500 mg) of Roche Pharmaceuticals, Roche
      Laboratories Inc. 340 Kingsland Street, New Jersey; in healthy,adult, human subjects under
      fed conditions with a wash out period of 10 days between two periods.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax and AUC parameters</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Naproxen Sodium 550 mg Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naproxen Sodium 550 mg Tablets of Dr. Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anaprox DS 550mg Tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anaprox DS 550mg Tablets of Roche Pharmaceuticals Inc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen Sodium</intervention_name>
    <description>Naproxen Sodium Tablets 550 mg</description>
    <arm_group_label>Naproxen Sodium 550 mg Tablets</arm_group_label>
    <arm_group_label>Anaprox DS 550mg Tablets</arm_group_label>
    <other_name>Anaprox DS 550 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy human subjects within the age range of 18 to 45 years.

          -  Non-smokers since at least six months.

          -  Willingness to provide written informed consent to participate in the study.

          -  Body-mass index of ≥ 18.5 kg/m2 and ≤ 24.9 kg/m2, witQ body weight not less than 50
             kg.

          -  Absence of significant disease or clinically significant abnormal laboratory values on
             laboratory evaluations, medical history or physical examination during the screening.

          -  Normal 12-lead ECG or one with abnormality considered to be clinically insignificant.

          -  Normal chest X-ray PA view.

          -  Comprehension of the nature and purpose of the study and compliance with the
             requirement of the protocol.

          -  Female Subjects:

               -  of child bearing potential practicing an acceptable method of birth control for
                  the duration of the study as judged by the investigator(s) such as condoms, foams
                  jellies, diaphragm, intrauterine device {IUD}, or abstinence or postmenopausal
                  for at least 1 year, or surgically sterile {bilateral tubal ligation, bilateral
                  oophorectomy, or hysterectomy has been performed on the subject.

        Exclusion Criteria:

          -  Personal/family history of allergy or hypersensitivity to Naproxen sodium or allied
             drugs.

          -  Past history of anaphylaxis or angioedema.

          -  Any major illness in the past three months or any clinically significant ongoing
             chronic medical illness e.g. congestive heart failure, hepatitis, pancreatitis etc.

          -  Presence of any clinically significant abnormal values during screening e.g
             significant abnormality of liver Function Test (LFT), Renal (kidney) Function Test
             (RFT), etc.

          -  Any cardiac, renal or liver impairment any other organ or system impairment.

          -  History of seizure or psychiatric disorders.

          -  Presence of disease markers of HIV 1 and 2, and hepatitis B and C virus.

          -  Consumption of alcohol for more than two years, or consumption of more than three
             alcoholic drinks per day or consumption of alcohol within 48 hours prior to dosing and
             during the study {one drink is equal to one unit of alcohol {one glass wine half pint
             beer, and one measure (one ounce) of spirit].

          -  Consumption of xanthine containing derivatives (coffee, tea, cola drinks, chocolate)
             within 48 hours before check-in of each period.

          -  Use of any recreational drug or a history of drug addiction.

          -  Participation in any clinical trial within the past 3 months.

          -  Inaccessibility of veins in left and right arm.

          -  Donation of blood (one unit or 350 mL) within 3 months prior to receiving the first
             dose of study medication.

          -  Receipt of any prescription drug therapy within four weeks or over-the-counter {OTC)
             drugs within two weeks prior to receiving the first dose of study medication or
             repeated use of drugs within the last four weeks.

          -  An unusual diet, for whatever reason e.g. low sodium diet for two weeks prior to
             receiving any medication and through out subject's participation in the study.

          -  Consumption of grapefruit-containing food or beverages within 7 days prior to
             receiving the first dose of study medication in both the periods.

          -  Recent history of dehydration from diarrhoea, vomiting or any other reason within a
             period of 24 hours prior to the study.

          -  Female volunteers demonstrating a positive pregnancy screen or currently
             breast-feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Umesh Dhakate, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wellquest Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wellquest Clinical Research</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400 013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2010</study_first_submitted>
  <study_first_submitted_qc>January 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2010</study_first_posted>
  <last_update_submitted>January 19, 2010</last_update_submitted>
  <last_update_submitted_qc>January 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Vice President - Research &amp; Development</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Naproxen</keyword>
  <keyword>crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

